Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chen, Xuejun
HDM3014-301, NCT06648772: Efficacy and Safety of Roflumilast Cream 0.3% in Subjects with Plaque Psoriasis: a Phase 3 Study	Recruiting	3	189	RoW	Roflumilast Cream 0.3%, Zoryve, Vehicle cream	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Plaque Psoriasis	06/25	07/25
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer	Recruiting	2	88	RoW	RC88, RC88 for Injection	RemeGen Co., Ltd.	Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer	06/26	12/26
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer	Withdrawn	2	177	RoW	Balstilimab, Balstilimab + Zalifrelimab	Agenus Inc., Betta Pharmaceuticals Co., Ltd.	Cervical Cancer	12/24	12/24